69 results about "Methyl thiazolyl tetrazolium" patented technology

The invention discloses a graphene quantum dot nuclear targeting medicine carrying system as well as a preparation method and application thereof. The preparation method comprises the following steps: firstly, sterilizing an aqoeous solution of a graphene quantum dot and an aqoeous solution of an anti-cancer medicine; secondly, mixing the aqoeous solution of the graphene quantum dot and the aqoeous solution of the anti-cancer medicine according to the mass ratio of (5:1)-(50:1) to obtain a medicine carrying system; thirdly, co-cultivating the medicine carrying system and cells, detecting the toxicity of the cells by using an MTT (Methyl Thiazolyl Tetrazolium) method and detecting a medicine loaded into the cells by using a fluorescent microscope. According to the invention, by virtue of the characteristic that the graphene quantum dot has a single-atom planar structure, the graphene quantum dot and a micromolecule anticancer medicine with a polycyclic planar structure are combined by bonds to form the medicine carrying system which can stably exist in the aqoeous solution. The graphene quantum dot has a medicine carrying function; meanwhile, the graphene quantum dot has a special structure, so that the toxicity of the medicine to the cells can be increased. The medicine carrying system has the advantages of lower toxicity, simple preparation method, easiness for implementation and double functions of carrying the medicine and enhancing the toxicity of the medicine to the cells.

The invention discloses a fluoroquinolone-methyl thiazolyl tetrazolium heterozygous derivative as shown in formula I. The derivate is characterized in that pharmacophores of fluoroquinolone and methylthiazolyl tetrazolium type medicines are interconnected through proper connection structures; the bioactivity experiment verifies that the compound has bacteria and fungus inhibiting activity and hasgood application prospect.

The invention relates to a detection method for the cytotoxicity of gas-liquid contact type cigarettes under full-smoke exposure, belonging to the technical field of safety evaluation of cigarette smoke. The detection method provided by the invention comprises the following steps of: firstly, setting cigarette suction parameters to carry out suction on a cigarette; diluting the smoke by clean air with the flow speed of 0-1000 mL/min and transferring the diluted cigarette full smoke into a full-smoke exposure bottle disclosed in the patent with the patent number of ZL201120063251.6 to come into contact and exposure with suspension cells in the bottle, wherein the exposure time is 5 min; after the exposure, carrying out neutral erythrocyte toxicity test or MTT (Methyl Thiazolyl Tetrazolium) cytotoxicity test according to a regular method; analyzing a dosage reaction relation between smoke exposure amount and cytotoxicity according to the following formula: full-smoke dilution multiple=( flow speed of smoke + flow speed of clean air)/flow speed of smoke; smoke exposure amount under exposure of 10 mL of a cell suspension solution for 5 min=TPM (Total Particulate Matter) amount of single cigarette/suction times of single cigarette*6 suctions/10 mL; and representing the extent of cytotoxicity by a cell inhibition ratio CI. The detection method provided by the invention has the advantages of simplicity, feasibility, low cost and the capability of providing technical supports for the safety evaluation of cigarette smoke.

The invention relates to a mononuclear copper complex and a preparation method and application thereof. Chemical formulas of the mononuclear copper complex are respectively [CuLCl](ClO4)(1) and [CuL(acac)](PF6)(2), wherein L is N,N-(2-pyridyl)-1-(1-naphthyl) ethylamine, acac is acetylacetone, and PF6 is hexafluorophosphate radical. The complex (1) crystal is of an orthorhombic system, a space point group is Pbca, cell parameters are described in the specification; the complex (2) crystal is of a monoclinic system, a space point group is P2(1)/c, and cell parameters are described in the specification. A plurality of spectroscopic methods represent that the mononuclear copper complex has a strong bonding function for CT-DNA (Circulating Tumor-Desoxvribose Nucleic Acid); agar gel electrophoresis experiments prove that the mononuclear copper complex has a remarkable cutting effect on pBR322DNA by using an oxidation cutting principle; MTT (Methyl Thiazolyl Tetrazolium) experiments prove that the mononuclear copper complex has a better anti-tumor activity to multiple kinds of cells, and can be used as a potential anti-tumor medicine.

The invention discloses a method for rapidly determining drug tolerance of a strain. The method comprises the following steps: A, preparing nutrient fluid containing methyl thiazolyl tetrazolium; B, preparing bacterial suspension; C, preparing antibiotic solution; D, adding the nutrient fluid containing the methyl thiazolyl tetrazolium, the antibiotic solution and the bacterial suspension into holes of a culture plate, and performing serial dilution on the antibiotic solution; and E, scanning and determining the diluent in real time, and determining the drug tolerance of the strain to antibiotic according to the scanning result. Compared with the prior art, the method has the advantages of simply, rapidly, economically and high-efficiently determining the drug tolerance of the strain.

The invention relates to the technical field of bioengineering and discloses a method for improving camptothecin content in hairy roots of the new-type medicine source plant ophiorrhiza pumila of camptothecin. The method disclosed by the invention comprises the following steps of: cloning coding frame sequences of genes of ophiorrhiza japonica strictosidine synthase and geraniol-10-hydroxylase in catharanthus roseus to build a plant bivalent efficient expression vector containing the genes, carrying out genetic transformation on ophiorrhiza pumila via an agrobacterium rhizogenes mediated method to acquire the hairy roots of the ophiorrhiza pumila for transforming CrSTR and CrG10H genes; and inducing and treating high-yield camptothecin strains by adopting plant hormones to acquire high-yield hairy roots with the camptothecin content of 4.703mg/g DW. The MTT (Methyl Thiazolyl Tetrazolium) detection proves that camptothecin crude extract acquired via a transgenosis manner is good in biological activity and the lethality to cancer cells reaches 35.9%. By adopting the method disclosed by the invention, a new medicine source for acquiring the camptothecin is provided and a new method for producing anti-cancer medicine camptothecin in important clinical demand is provided.

The invention provides a multifunctional non-oxidative type sterilization algicide and belongs to the technical field of water processing. The multifunctional non-oxidative type sterilization algicide is composed of, by weight, 15-30% of compound quaternary ammonium salt, 3-4% of isothiazolinone, 6-8% of penetrating agents T, 15-30% of polymaleic anhydride, 5-10% of zinc salt, 3-5% of methyl thiazolyl tetrazolium, 3-5% of composite organic amine and the balance water. The multifunctional non-oxidative type sterilization algicide integrates sterilization, algae removal, scale inhibition and corrosion inhibition functions. All components of the sterilization algicide have good intermiscibility, cooperativity and complementarity, and the sterilization algicide can replace an existing sterilization algicide with a single function. Both the formula and the preparing method of the sterilization algicide are environmentally friendly, the adopted compound raw materials do not contain phosphorus, eutrophication of water is avoided, the environment cannot be polluted by discharged water, the preparing method is simple and easy to implement, a clean process is achieved, and three industrial wastes are avoided.

The invention discloses a gene of sika deer IGF (Insulin-like Growth Factor)-1 mature peptide. An EcoR I restriction enzyme cutting site and a base sequence of code Asn are added at the end 5 of a forward primer; a Hind III restriction enzyme cutting site and a sequence of a termination codon are added at the end 5 of a reverse primer; a base sequence 234bp gene for expressing the sika deer IGF-1 mature peptide is cloned; an expression vector, namely pET-32a-IGF-1 is constructed and is induced and expressed in Escherichia coli Rosetta to obtain the sika deer IGF-1 mature peptide. The EcoR I restriction enzyme cutting site and the Hind III restriction enzyme cutting site are introduced and an Asn is added in front of natural IGF-1, so that a specific cracking part of hydroxylamine is formed, and further the cutting cost of protein is reduced, the influence on protein renaturation caused by extra amino acid sequence is reduced and the state of the protein in a natural state is kept. The pET-32a as an expression vector is expressed in the Escherichia coli Rosetta, so that the protein content can reach over 50 percent of soluble protein of thallus; and through the detection by adopting an MTT (Methyl Thiazolyl Tetrazolium) method, the multiplication rate of N1H3T3 cells can be increased.

The invention discloses application of aplysin in preparation of a medicine for treating glioma, aiming at researching the anti-tumor activity of aplysin to glioma. The MTT (Methyl Thiazolyl Tetrazolium) experiment shows that the inhibition ratio of aplysin to C6 cell is increased along with the raise of the concentration of aplysin; after the concentration is raised beyond 80mcg/m, the inhibition ratio of C6 cell does not raise obviously, namely, the most effective anti-tumor concentration of aplysin is 80mc/ml; the best effect appears in 48 hours in light of the action time; with the prolonging of the time, the cell inhibition ratio does not raise obviously. The animal experiment result shows that after the dose of aplysin is increased, the life time of a rat is prolonged, the weight of glioma is reduced, and the infiltration of lymphocyte is improved; 40mg/kg.bw is the best dose for reaching the best effect. The experiment shows that aplysin belongs to natural marine drugs and has small toxic and side effects, so that aplysin can be used as the medicine for treating glioma; aplysin is good in market application prospect.

The invention discloses an application of a compound shown in formula I shown in the specification in preparation of a drug for inhibiting tumor cell proliferation or prevention and/or treatment of tumor. In the formula I, R1 is acetyl or H, and R2 is acetyl or H. By the proving of the experiment, an MTT (methyl thiazolyl tetrazolium) method is adopted to test the inhabitation of compounds 11-O-acetylcyathatriol and 15-O-acetylcyathatriol to human hepatoma cells HeG2, human prostatic cancer cells PC3, human lung carcinoma cells A549, human colorectal cancer cells HCT-15, human cervical carcinoma cells Hela, human leukemia cells K562, human gastric carcinoma cells SGC-7901 and human breast cancer cells MCF-7. The experiment proves that the compounds play the role of proliferation and inhabitation of the eight cancer cells. Compared with other prepared antitumor drugs reported by the literature, the compound has the advantages of simpleness and easiness in obtaining and obvious activity.

The invention discloses an application of Pedinophyllol B in preparation of a vascular protective drug and belongs to the field of drugs. MTT (methyl thiazolyl tetrazolium) assay and LDH (lactic dehydrogenase) activity detection prove that Pedinophyllol B has an protective effect on H2O2 oxidative damage ECV-304 cells; measurement for MDA (malondialdehyde) content, SOD (superoxide dismutase) activity and GSH-Px (glutathion peroxidase) activity of a cell supernatant proves that Pedinophyllol B has the free radical scavenging property and the antioxidant property of active oxygen and can be further researched and developed to prepare the vascular protective drug.

The invention discloses an application of a purslane alkaloid monomeric compound in the preparation of an anti-tumor medicament, wherein the purslane alkaloid monomeric compound refers to purslane amide B and aurantiamide acetate, and inhibitory activities of the two monomeric compounds on human lung adenocarcinoma cells (A549) and human leukemia cell lines (K562) are detected by using MTT (methyl thiazolyl tetrazolium) ([3-(4,5)-dimethyl-2-thiazole-(2,5)-phenyl tetrazolium bromide]. The results show that the two monomeric compounds have an obvious growth inhibition, thereby indicating that the two monomeric compounds of purslane amide B and aurantiamide acetate can be applied to the preparation of the anti-tumor medicament.

The invention relates to the field of fermenting engineering, in particular to a method for screening bacterial strains with high output of low-temperature MDH (malate dehydrogenase). The MDH is a keyenzyme for cell center oxidizing channels, and is closely related with the movement of bacterial flagellum in related reports. The method has the advantages that the bromocresol green is used for primary screening, and the bacterial strain with stronger acid production property is screened out; the power property of the bacterial strain is detected by MTT (methyl thiazolyl tetrazolium), the screening is performed for the second time, and the bacterial strain with stronger power property is selected to test the activity of the enzyme; the low-temperature bacterial strain with high output of MDHs can be accurately screened out by double screening; finally, the activity of the enzyme is detected to finally determine the high-output bacterial strain; the bacterial strains with high output oflow-temperature intracellular MDH can be conveniently and accurately screened out within 20 days, and the blank in the related field of screening of culture mediums by the MDH is filled.

The invention relates to a preparation method of an oyster shell extract. The method comprises the following steps of: adding water-containing solution of alcohol into oyster shell powder in a material to liquid ratio of 1g:2-20mL, performing reflux extraction and filtering or centrifugally separating liquid out; and concentrating the obtained liquid under reduced pressure, extracting with an organic solvent, separating an organic solvent layer out, concentrating under reduced pressure and drying to obtain the oyster shell extract. Tests by a lissamine rhodamine B method indicate that the prepared oyster shell extract has the function of inhibiting cell proliferation of a plurality of tumor cell strains; and tests by a methyl thiazolyl tetrazolium method indicate that the oyster shell extract has the function of inhibiting cell proliferation of human umbilical vein endothelial cells. Experiments indicate that the oyster shell extract can play a role in resisting tumors by inhibiting tumor cell proliferation and angiogenesis. Therefore, the oyster shell extract of the invention can be taken as a cell proliferation inhibitor, an angiogenesis inhibitor and an anti-tumor agent.

The invention relates to a method for catalytic regeneration of NAD(P)H by a supported metal catalyst, which comprises the following steps: reducing oxidized coenzyme under the action of the supported metal catalyst to obtain reduced coenzyme NAD(P)H; wherein the supported metal catalyst is a supported bimetallic nano catalyst; The coenzyme regenerated by the method disclosed by the invention has the electron transfer activity of the coenzyme after being tested by an MTT (Methyl Thiazolyl Tetrazolium) method. The method for catalytically regenerating the NAD (P) H by the supported metal catalyst has the advantages of mild reaction conditions, high efficiency, simplicity and convenience in operation, high selectivity, environmental friendliness and the like.

The invention relates to a screening method of positive substances for a pyrolyzate trapping substance cytotoxicity test. The screening method comprises the following steps of: determining thermal cracking temperature according to the combustion state of substances participating in combustion; selecting some commonly used positive substances used for the cytotoxicity test as alternative substances of the positive substances used for the pyrolyzate trapping substance cytotoxicity test; determining whether to enter the follow-up screening step according to the boiling point, melting point, heat stability and other physicochemical properties of the alternative substances; performing the heat cracking test for the substances of which relevant physicochemical properties are failed to be inquired or the substances which have the boiling point below the combustion temperature and are not decomposed or decomposed a little during combustion; enriching the pyrolyzate; separating and analyzing through a gas chromatography-mass spectrometer; performing the heat cracking test for the substances failed to be decomposed or decomposed a little under the combustion temperature; performing MTT (Methyl Thiazolyl Tetrazolium) cytotoxicity test for the trapped pyrolyzate; obtaining the substances with cell inhibition not less than 80% to be used as the positive substances for the pyrolyzate trapping substance cytotoxicity test. By adopting the method, the positive substances for the pyrolyzate trapping substance cytotoxicity test can be screened effectively.

The invention discloses application of a fructus akebiae extract in preparation of a drug for treating primary hepatic carcinoma. The application is that the fructus akebiae extract is taken as an active ingredient to prepare a drug preparation for treating the primary hepatic carcinoma. A cancer cell growth and proliferation MTT (methyl thiazolyl tetrazolium) detection method is adopted by the invention, and the experiment demonstrates that the fructus akebiae extract has the significant effect of restraining malignant cell proliferation of the primary hepatic carcinoma, and is expected to be applied to preparation of the drug preparation for treating the primary hepatic carcinoma by restraining the malignant cell proliferation of the primary hepatic carcinoma; and a new medicinal value is opened up for the fructus akebiae extract.

The invention discloses gamma-hydroxy olic acid ester derivatives having antitumor activity and the use thereof in the preparation of antitumor medicines, and belongs to the field of biochemical technology. The structure of the gamma-hydroxy olic acid ester derivatives is shown in the description. The results of classic methyl thiazolyl tetrazolium (MTT) tumor cell medicine screening experiments, AnnexinV/PI double-staining cell apoptosis measurement experiments, cell periodical detection experiments and in-vivo antitumor experiments prove that the gamma-hydroxy olic acid ester derivatives have proliferation inhibition effects on breast cancer, bladder cancer and liver cancer and can be used in the preparation of antitumor medicines as an active ingredient.